Mechanisms of resistance of malaria parasites to antifolates

Pharmacological Reviews

Volumn 57, Issue 1, 2005, Pages 117-145

  Gregson, Aric ^a   Plowe, Christopher V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; AMODIAQUINE; ANTIMALARIAL AGENT; BIGUANIDE; CHLORCYCLOGUANIL; CHLOROQUINE; CHLORPROGUANIL; CYCLOGUANIL; DAPSONE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; ERYTHROMYCIN; FOLIC ACID ANTAGONIST; HALOFANTRINE; MEFLOQUINE; MEPACRINE; N [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] N' ISOPROPYLIMIDOCARBONIMIDIC DIAMIDE; PHOSPHOTRANSFERASE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; QUININE; SULFADOXINE; SULFALENE; SULFAMETHOXAZOLE; SULFAMIDOCHRYSOIDINE; SULFANILAMIDE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG;

BIOSYNTHESIS; BLOOD SMEAR; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENDEMIC DISEASE; ENZYME KINETICS; FOLATE METABOLISM; GENE AMPLIFICATION; GENE MUTATION; GENOME; GENOTYPE; HUMAN; IC 50; LIFE CYCLE; MALARIA; MUTATION RATE; NONHUMAN; PARASITE SURVIVAL; PLASMODIUM FALCIPARUM; POINT MUTATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; MALARIA; MULTIENZYME COMPLEXES; PLASMODIUM FALCIPARUM; POINT MUTATION; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 14144253009     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.57.1.4     Document Type: Review

References (317)

1. Abdalla S, Weatherall DJ, Wickramasinghe SN, and Hughes M (1980) The anaemia of P. falciparum malaria. Br J Haematol 46:171-183.
2. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, and White N (2004) Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363:9-17.
3. Archibald HM (1951) Field trials on a new schizonticide. Br Med J 2:821-823.
4. Ariey F, Randrianarivelojosia M, Duchemin JB, Rakotondramarina D, Ouledi A, Robert V, Jambou R, Jahevitra M, Andrianantenaina H, Raharimalala L, et al. (2002) Mapping of a Plasmodium falciparum pfcrt K76T mutation: a useful strategy for controlling chloroquine resistance in Madagascar. J Infect Dis 185:710-712.
5. Avise JC (1991) Ten unorthodox perspectives on evolution prompted by comparative population genetic findings on mitochondrial DNA. Annu Rev Genet 25:45-69.
6. Baca AM, Sirawaraporn R, Turley S, Sirawaraporn W, and Hol WG (2000) Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfadrug action. J Mol Biol 302:1193-1212.
7. Baird JK, Basri H, Jones TR, Purnomo Bangs MJ, and Ritonga A (1991) Resistance to antimalarials by Plasmodium falciparum in Arso Pir, Irian Jaya, Indonesia. Am J Trop Med Hyg 44:640-644.
8. Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, and Mazabraud A (1995) Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69:135-138.
9. Basco LK and Ringwald P (1998) Molecular epidemiology of malaria in Yaounde, Cameroon II. Baseline frequency of point mutations in the dihydropteroate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg 58:374-377.
10. Bishop A (1958) An analysis of the development of resistance to metachloridine in clones of Plasmodium gallinaceum. Parasitology 48:210-234.
11. Bishop A (1962) An analysis of the development of resistance to proguanil and pyrimethamine in Plasmodium gallinaceum. Parasitology 52:495-518.
12. Bishop A and Birkett B (1947) Acquired resistance to Paludrine in Plasmodium gallinaceum: acquired resistance and persistence after passage through the mosquito. Nature (Lond) 159:884-885.
13. Bloland PB, Ettling M, and Meek S (2000) Combination therapy for malaria in Africa: hype or hope? Bull W H O 78:1378-1388.
14. Bradley-Moore AM, Greenwood BM, Bradley AK, Akintunde A, Attai ED, Fleming AF, Flynn FV, Kirkwood BR, and Gilles HM (1985) Malaria chemoprophylaxis with chloroquine in young Nigerian children. IV. Its effect on haematological measurements. Ann Trop Med Parasitol 79:585-595.
15. Brasseur P, Guiguemde R, Diallo S, Guiyedi V, Kombila M, Ringwald P, and Olliaro P (1999) Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans R Soc Trop Med Hyg 93:645-650.
16. Breman JG (2001) The ears of the hippopotamus: manifestations, determinants and estimates of the malaria burden. Am J Trop Med Hyg 64:1-11.
17. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, and Hyde JE (1994) Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 224:397-405.
18. Bukirwa H, Garner P, and Critchley J (2004) Chlorproguanil-dapsone for treating uncomplicated malaria. Cochrane Database Syst Rev 4:CD004387.
19. Bunnag D, Harinasuta T, Pinichpongse S, and Suntharasami P (1980) Effect of primaquine on gametocytes of Plasmodium falciparum in Thailand. Lancet 2:91.
20. Burgess RW and Young MD (1959) The development of pyrimethamine resistance by Plasmodium falciparum. Bull WHO 20:37-46.
21. Bzik DJ, Li WB, Horii T, and Inselburg J (1987) Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA 84:8360-8364.
22. Campbell CC, Chin W, Collins WE, Teutsch SM, and Moss DM (1979) Chloroquine-resistant Plasmodium falciparum from East Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist. Lancet 2:1151-1154.
23. Canfield CJ, Milhous WK, Ager AL, Rossan RN, Sweeney TR, Lewis NJ, and Jacobus DP (1993) PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 49:121-126.
24. Canfield CJ, Pudney M, and Gutteridge WE (1995) Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 80:373-381.
25. Carrington HC, Crowther AF, and Stacey GJ (1954) Synthetic antimalarials. Part XLIX. The structure and synthesis of the dihydrotriazine metabolite proguanil. J Chem Soc Part 1:1017-1031.
26. Chaparro J, Rojas MO, and Wasserman M (2001) Plasmodium falciparum: underestimation of dihydrofolate reductase and dihydropteroate synthase polymorphism in field samples: a technical shortcoming of nested per assays with mutation-specific primers. Exp Parasitol 99:115-122.
27. Chen GX, Mueller C, Wendlinger M, and Zolg JW (1987) Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum. Mol Pharmacol 31:430-437.
28. Chin W, Contacos PG, Coatney GK, Jeter MH, and Alpert E (1967) Evaluation of CI-564, a 1:1 mixture of cycloguanil pamoate (CI-501) and 4,4′-diacetylaminodiphenylsulfone (CI-556), against multiresistant falciparum malarias. Am J Trop Med Hyg 16:580-584.
29. Chin W, Contacos PG, Coatney GR, and King HK (1966) The evaluation of sulfonamides, alone or in combination with pyrimethamine, in the treatment of multi-resistant falciparum malaria. Am J Trop Med Hyg 15:823-829.
30. Chulay JD, Watkins WM, and Sixsmith DG (1984) Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg 33:325-330.
31. Clyde DF (1967a) Malaria in Tanzania, in Malaria, in Tanzania (Clyde DF ed) pp 167, Oxford University Press, London.
32. Clyde DF (1967b) Antimalarial effect of diaphenylsulfone and three sulfonamides among semi-immune Africans. Am J Trop Med Hyg 16:7-10.
33. Clyde DF (1972a) Responsibility for failure of sulphonamides in falciparum malaria; host or parasite? Trans R Soc Trop Med Hyg 66:806-807.
34. Clyde DF (1972b) The problem of drug-resistant malaria. Am J Trop Med Hyg 21:736-743.
35. Clyde DF, Hlaing N, and Tin F (1972) Resistance to chloroquine of Plasmodium falciparum from Burma. Trans R Soc Trop Med Hyg 66:369-370.
36. Clyde DF and Shute GT (1954) Resistance of East African varieties of Plasmodium falciparum to pyrimethamine. Trans R Soc Trop Med Hyg 48:495-500.
37. Clyde DF and Shute GT (1957) Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg 51:505-513.
38. Coatney GR, Myatt AV, Hernandez T, Jeffery GM, and Cooper WC (1952) Studies on the compound 50-63. Trans R Soc Trop Med Hyg 46:496-497.
39. Coggeshall LT, Maier J, and Best CA (1941) The effectiveness of two new types of chemotherapeutic agents in malaria. JAMA (J Am Med Assoc) 117:1077-1081.
40. Cortese JF, Caraballo A, Contreras CE, and Plowe CV (2002) Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186:999-1006.
41. Cortese JF and Plowe CV (1998) Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol Biochem Parasitol 94:205-214.
42. Covell G, Coatney GR, Field JW, and Singh J (1955) Chemotherapy of Malaria. World Health Organization, Geneva, Switzerland.
43. Covell G, Nicol WD, Shute PG, and Maryon M (1949) Studies on a West African strain of Plasmodium falciparum. II. The efficacy of Paludrine (proguanil) as a therapeutic agent. Trans R Soc Trop Med Hyg 42:465-476.
44. Cowman AF, Morry MJ, Biggs BA, Cross GA, and Foote SJ (1988) Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 85:9109-9113.
45. Crabb BS and Cowman AF (1996) Characterization of promoters and stable transfection by homologous and nonhomologous recombination in Plasmodium falciparum. Proc Natl Acad Sci USA 93:7289-7294.
46. Curd FHS (1943) The activity of drugs in the malaria of man, monkeys and birds. Ann Trop Med Parasitol 37:115-143.
47. Curtis J, Duraisingh MT, Trigg JK, Mbwana H, Warhurst DC, and Curtis CF (1996) Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania. Trans R Soc Trop Med Hyg 90:678-680.
48. Curtis J, Duraisingh MT, and Warhurst DC (1998) In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. J Infect Dis 177:1429-1433.
49. Curtis J, Maxwell CA, Msuya FH, Mkongewa S, Alloueche A, and Warhurst DC (2002) Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment. J Infect Dis 186:1861-1864.
50. Dallas WS, Gowen JE, Ray PH, Cox MJ, and Dev IK (1992) Cloning, sequencing and enhanced expression of the dihydropteroate synthase gene of Escherichia coli mc4100. J Bacteriol 174:5961-5970.
51. Davey DG and Robertson GI (1957) Experiments with antimalarial drugs in man. IV. An experiment to investigate the prophylactic value of proguanil against a strain of Plasmodium falciparum known to be resistant to therapeutic treatment. Trans R Soc Trop Med Hyg 51:463-466.
52. de Alencar FE, Cerutti C Jr, Durlacher RR, Boulos M, Alves FP, Milhous W, and Pang LW (1997) Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 175:1544-1547.
53. DeGowin RL and Powell RD (1964) Drug-resistant falciparum malaria. J Lab Clin Med 64:851-852.
54. Delannoy A and Hugon J (1954) Trials of prophylaxis of malaria with pyrimethamine in a rural area in the Belgian Congo. Ann Soc Belge Med Trop 34:397-405.
55. Delfino RT, Santos-Filho OA, and Figueroa-Villar JD (2002) Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum dhfr. Biophys Chem 98:287-300.
56. Dieckmann A and Jung A (1986a) Stage-specific sensitivity of Plasmodium falciparum to antifolates. Z Parasitenkd 72:591-594.
57. Dieckmann A and Jung A (1986b) The mechanism of pyrimethamine resistance in Plasmodium falciparum. Parasitology 93:275-278.
58. Diggens SM, Gutteridge WE, and Trigg PI (1970) Altered dihydrofolate reductase associated with a pyrimethamine-resistant Plasmodium berghei berghei produced in a single step. Nature (Lond) 228:579-580.
59. Diourte Y, Djimde A, Doumbo OK, Sagara I, Coulibaly Y, Dicko A, Diallo M, Diakite M, Cortese JF, and Plowe CV (1999) Pyrimethamine-sulfadoxine efficacy and selection for mutations in plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg 60:475-478.
60. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, et al. (2001a) A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257-263.
61. Djimde A, Doumbo OK, Steketee KW, and Plowe CV (2001b) Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 358:890-891.
62. Djimde AA, Dolo A, Ouattara A, Diakite S, Plowe CV, and Doumbo OK (2004) Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. J Infect Dis 190:853-855.
63. Dobrovolny CG, White WC, and Coatney GR (1953) Chloroquine and chlorguanide as suppressants of malaria in Guatemala. Am J Trop Med Hyg 2:808-845.
64. Duffy PE and Mutabingwa TK (2004) Drug combinations for malaria: time to act? Lancet 363:3-4.
65. Earle DPJ, Berliner RW, Taggart JV, Zubrod CG, Welch WJ, Bigelow FS, Kennedy TJJ, and Shannon JA (1948) Studies on the chemotherapy of the human malarias. X. The suppressive antimalarial effect of paludrine. J Clin Investig 27:130-133.
66. Edstein MD, Yeo AE, Kyle DE, Looareesuwan S, Wilairatana P, and Rieckmann KH (1996) Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. Trans R Soc Trop Med Hyg 90:418-421.
67. Eldin de Pecoulas P, Basco LK, Abdallah B, Dje MK, Le Bras J, and Mazabraud A (1995) Plasmodium falciparum: detection of antifolate resistance by mutation-specific restriction enzyme digestion. Exp Parasitol 80:483-487.
68. Enosse S, Butcher GA, Margos G, Mendoza J, Sinden RE, and Hogh B (2000) The mosquito transmission of malaria: the effects of atovaquone-proguanil (Malarone) and chloroquine. Trans R Soc Trop Med Hyg 94:77-82.
69. Eppes RB, DeGowin RL, Powell RD, and Legters LJ (1966) Clinical studies with a drug-resistant strain of Plasmodium falciparum from Vietnam. Mil Med 131:362-371.
70. Eyles DE, Hoo CC, Warren M, and Sandosham AA (1963) Plasmodium falciparum resistant to chloroquine in Cambodia. Am J Trop Med Hyg 12:840.
71. Ferlan JT, Mookherjee S, Okezie IN, Fulgence L, and Sibley CH (2001) Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210. Mol Biochem Parasitol 113:139-150.
72. Ferone R (1977) Folate metabolism in malaria. Bull World Health Organ 55:291-298.
73. Ferone R, Burchall JJ, and Hitchings GH (1969) Plasmodium berghei dihydrofolate reductase. Isolation, properties and inhibition by antifolates. Mol Pharmacol 5:49-59.
74. Fidock DA and Wellems TE (1997) Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci USA 94:10931-10936.
75. Field JW and Edeson JFB (1949) Paludrine resistant falciparum malaria. Trans R Soc Trop Med Hyg 43:233-236.
76. Figtree M, Pasay CJ, Slade R, Cheng Q, Cloonan N, Walker J, and Saul A (2000) Plasmodium vivax synonymous substitution frequencies, evolution and population structure deduced from diversity in ama 1 and msp 1 genes. Mol Biochem Parasitol 108:53-66.
77. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, and Pasvol G (2002) Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 1:1.
78. Fogh S, Jepsen S, and Effersoe P (1979) Chloroquine-resistant Plasmodium falciparum malaria in Kenya. Trans R Soc Trop Med Hyg 73:228-229.
79. Fogh S, Jepsen S, and Mataya RH (1984) R-III chloroquine-resistant Plasmodium falciparum malaria from northern Malawi. Trans R Soc Trans Med Hyg 78:282.
80. Foote SJ, Galatis D, and Cowman AF (1990) Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 87:3014-3017.
81. Foster S (1994) Economic prospects for a new antimalarial drug. Trans R Soc Trop Med Hyg 88 (Suppl 1):S55-S56.
82. Garfield RM and Vermund SH (1983) Changes in malaria incidence after mass drug administration in Nicaragua. Lancet 2:500-503.
83. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, Rosenthal PJ, and Kamya MR (2003) Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg 68:127-132.
84. Gassis S and Rathod PK (1996) Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance. Antimicrob Agents Chemother 40:914-919.
85. Geary TG, Divo AA, and Jensen JB (1989) Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture. Am J Trop Med Hyg 40:240-244.
86. Goodwin LG (1952a) Daraprim, clinical trials and pharmacology. Trans R Soc Trop Med Hyg 46:485-495.
87. Goodwin LG (1952b) Daraprim (B.W. 50-63), a new antimalarial (trials in human volunteers). Br Med J 1:732-734.
88. Greenberg AE, Ntumbanzondo M, Ntula N, Mawa L, Howell J, and Davachi F (1989) Hospital-based surveillance of malaria-related paediatric morbidity and mortality in Kinshasa, Zaire. Bull World Health Organ 67:189-196.
89. Greenberg J and Richeson EM (1950) Potentiation of the antimalarial activity of sulfadiazine by 2,4-diamino-5-aryloxypyrimidines. J Pharmacol Exp Ther 99:444-449.
90. Gritzmacher CA and Reese RT (1984) Protein and nucleic acid synthesis during synchronized growth of Plasmodium falciparum. J Bacteriol 160:1165-1167.
91. Gutteridge WE and Coombs GH (1977) Biochemistry of parasitic protozoa. Macmillan, London.
92. Gutteridge WE and Trigg PI (1971) Action of pyrimethamine and related drugs against Plasmodium knowlesi in vitro. Parasitology 62:431-444.
93. Harinasuta T, Suntharasamai P, and Viravan C (1965) Chloroquine-resistant falciparum malaria in Thailand. Lancet 2:657-660.
94. Harinasuta T, Viravan C, and Reid HA (1967) Sulphormethoxine in chloroquine-resistant falciparum malaria in Thailand. Lancet 1:1117-1119.
95. Hassan AM, Bjorkman A, and Wernsdorfer WH ( 1999) Synergism of benflumetol and artemether in Plasmodium falciparum. Am J Trop Med Hyg 61:439-445.
96. Hastings IM, Watkins WM, and White NJ (2002) The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci 337:505-519.
97. Hawking F (1947) Activation of Paludrine in vitro. Nature (Lond) 159:409.
98. Hekmat-Nejad M, Lee PC, and Rathod PK (1997) Plasmodium falciparum: direct cloning and expression of pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase domains. Exp Parasitol 85:303-305.
99. Hekmat-Nejad M and Rathod PK (1997) Plasmodium falciparum: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase. Exp Parasitol 87:222-228.
100. Hill J (1963) Chemotherapy of malaria. Part 2. The antimalarial drugs, in Experimental Chemotherapy (Schnitzer RJ and Hawkings F eds) pp 513-601, Academic Press, Inc., New York.
101. Hill RA and Goodwin MHJ (1937) "Prontosil" in treatment of malaria, report of 100 cases. South Med J 30:1170-1172.
102. Hitchings GH (1960) Pyrimethamine: the use of an antimetabolite in the chemotherapy of malaria and other infections. Clin Pharmacol Ther 1:570-589.
103. Hoshen MB, Stein WD, and Ginsburg H (1998) Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Parasitology 116:407-416.
104. Hurly MGD (1959) Potentiation of pyrimethamine by sulphadiazine in human malaria. Trans R Soc Trop Med Hyg 53:412-413.
105. Hyde JE (1990) The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther 48:45-59.
106. Hyde JE and Sims PF (2001) Sulfa-drug resistance in Plasmodium falciparum. Trends Parasitol 17:265-266.
107. Inselburg J, Bzik DJ, and Horii T (1987) Pyrimethamine resistant Plasmodium falciparum: overproduction of dihydrofolate reductase by a gene duplication. Mol Biochem Parasitol 26:121-134.
108. Iyer JK, Milhous WK, Cortese JF, Kublin JG, and Plowe CV (2001) Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358:1066-1067.
109. Jacobs RL, Alling DW, and Cantrell WF (1963) An evaluation of antimalarial combinations against Plasmodium berghei in the mouse. J Parasitol 49:920-925.
110. Jelinek T, Kilian AH, Curtis J, Duraisingh MT, Kabagambe G, von Sonnenburg F, and Warhurst DC (1999) Plasmodium falciparum: selection of serine 105 of dihydrofolate reductase during treatment of uncomplicated malaria with cotrimoxazole in Ugandan children. Am J Trop Med Hyg 61:125-130.
111. Jelinek T, Ronn AM, Curtis J, Duraisingh MT, Lemnge MM, Mhina J, Bygbjerg IC, and Warhurst DC (1997) High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance. Trop Med Int Health 2:1075-1079.
112. Jelinek T, Ronn AM, Lemnge MM, Curtis J, Mhina J, Duraisingh MT, Bygbjerg IC, and Warhurst DC (1998) Polymorphisms in the dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania. Trop Med Int Health 3:605-609.
113. Jepsen S, Fogh S, Peterslund N, and Black F (1983) RII-RIII chloroquine resistant Plasmodium falciparum malaria from East Africa: studies of the in vivo and in vitro response to chloroquine. Ann Trop Med Parasitol 77:349-354.
114. Jones RJ, Pullman TN, Whorton CM, Graige BJ, Alving AS, and Eichelberger L (1948) The therapeutic effectiveness of large doses of paludrine in acute attacks of sporozoite-induced vivax malaria (Chesson strain). J Clin Investig 27 (Suppl):51-55.
115. Jones SA (1953) Experiment to determine if a proguanil-resistant strain of P. falciparum would respond to large doses of pyrimethamine. Br Med J 1:977.
116. Jones SA (1954) Resistance of P. falciparum and P. malariae to pyrimethamine (daraprim) following mass treatment with this drug; a preliminary note. East Afr Med J 31:47-49.
117. Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Babirye JN, Staedke SG, and Rosenthal PJ (2001) The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Trans R Soc Trop Med Hyg 95:50-55.
118. Kan SC and Siddiqui WA (1979) Comparative studies on dihydrofolate reductases from Plasmodium falciparum and Aotus trivirgatus. J Protozool 26:660-664.
119. Kaneko A, Bergqvist Y, Takechi M, Kalkoa M, Kaneko O, Kobayakawa T, Ishizaki T, and Bjorkman A (1999) Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J Infect Dis 179:974-979.
120. Khalil I, Alifrangis M, Ronn AM, Gabar HA, Jelinek T, Satti GM, and Bygbjerg IC (2002) Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels and treatment outcome. Am J Trop Med Hyg 67:225-229.
121. Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM, and Bygbjerg IC (2003) Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine and sulfamethoxazole. Am J Trop Med Hyg 68:586-589.
122. Krungkrai J, Webster HK, and Yuthavong Y (1989) De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum. Mol Biochem Parasitol 32:25-37.
123. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185:380-388.
124. Kublin JG, Witzig RS, Shankar AH, Zurita JQ, Gilman RH, Guarda JA, Cortese JF, and Plowe CV (1998) Molecular assays for surveillance of antifolate-resistant malaria. Lancet 351:1629-1630.
125. Kun JF, Lehman LG, Lell B, Schmidt-Ott R, and Kremsner PG (1999) Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains. Antimicrob Agents Chemother 43:2205-2208.
126. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, and Dorsey G (2003) Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg 69:247-252.
127. Laing AB (1964) Antimalarial effect of sulphorthodimethoxine (Fanasil). Br Med J 2:1439-1440.
128. Laing AB (1965a) Treatment of acute falciparum malaria with sulphorthodimethoxine (Fanasil). Br Med J 1:905-907.
129. Laing AB (1965b) Treatment of acute falciparum malaria with diaphenylsulfone in North-East Tanzania. J Trop Med Hyg 68:251-253.
130. Laing AB (1968a) Hospital and field trials of sulformethoxine with pyrimethamine against Malaysian strains of Plasmodium falciparum and P. vivax. Med J Malaya 23:5-19.
131. Laing AB (1968b) Antimalarial effects of sulphormethoxine, diaphenylsulphone and separate combinations of these with pyrimethamine: a review of preliminary investigations carried out in Tanzania. J Trop Med Hyg 71:27-35.
132. Laing AB (1970a) Studies on the chemotherapy of malaria. (I). The treatment of overt falciparum malaria with potentiating combinations of pyrimethamine and sulphormethoxine or dapsone in the Gambia. Trans R Soc Trop Med Hyg 64:562-568.
133. Laing ABG (1970b) Studies on the chemotherapy of malaria. (II). Pyrimethamine resistance in the Gambia. Trans R Soc Trop Med Hyg 64:569-580.
134. Landau I, Lepers JP, Ringwald P, Rabarison P, Ginsburg H, and Chabaud A (1992) Chronotherapy of malaria: improved efficacy of timed chloroquine treatment of patients with Plasmodium falciparum infections. Trans R Soc Trop Med Hyg 86:374-375.
135. Li R, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, Athappilly F, Turley S, and Hol WG (2000) Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol 295:307-323.
136. Lin X, Parsels LA, Voeller DM, Allegra CJ, Maley GF, Maley F, and Chu E (2000) Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA. Nucleic Acids Res 28:1381-1389.
137. Looareesuwan S, Wilairatana P, Vanijanonta S, Kyle D, and Webster K (1992) Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet 339:369.
138. Lopez-Shirley K, Zhang F, Gosser D, Scott M, and Meshnick SR (1994) Antimalarial quinones: redox potential dependence of methemoglobin formation and heme release in erythrocytes. J Lab Clin Med 123:126-130.
139. Maegraith BG, Adams ARD, King JD, Tottey MM, Rigby DJ, and Sladden RA (1946) Paludrine in the treatment of malaria. Br Med J 1:903-905.
140. Maegraith BG, Adams ARD, King JD, Townshed RH, Davey TH, and Harvard RE (1945) Studies on the synthetic antimalarial drugs. XIV. Results of a preliminary investigation of the therapeutic action of 4888 (paludrine) on acute attacks of malignant tertian malaria. Ann Trop Med Parasitol 39:232-236.
141. Maier J and Riley E (1942) Inhibition of antimalarial action of sulfonamides by p-aminobenzoic acid. Proc Soc Exp Biol Med 50:152-154.
142. Marsh K (1992) Malaria-a neglected disease? Parasitology 104 (Suppl):S53-S69.
143. Martin DC and Arnold JD (1968a) The effect of parasite populations on the curative action of pyrimethamine. Trans R Soc Trop Med Hyg 62:379-384.
144. Martin DC and Arnold JD (1968b) Treatment of acute falciparum malaria with sulfalene and trimethoprim. J Am Med Assoc 203:476-480.
145. Martin DC and Arnold JD (1969) Trimethroprim and sulfalene therapy of Plasmodium vivax. J Clin Pharmacol 9:155-159.
146. Mberu EK, Nzila AM, Nduati E, Ross A, Monks SM, Kokwaro GO, Watkins WM, and Hopkins Sibley C (2002) Plasmodium falciparum: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance. Exp Parasitol 101:90-96.
147. McCutchan TF, Welsh JA, Dame JB, Quakyi IA, Graves PM, Drake JC, and Allegra CJ (1984) Mechanism of pyrimethamine resistance in recent isolates of Plasmodium falciparum. Antimicrob Agents Chemother 26:656-659.
148. McGready R, Brockman A, Cho T, Cho D, van Vugt M, Luxemburger C, Chongsuphajaisiddhi T, White NJ, and Nosten F (2000) Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 94:689-693.
149. McGregor IA and Smith DA (1952) Daraprim in treatment of malaria. A study of its effects in falciparum and quartan infections in West Africa. Br Med J 1:730-732.
150. McGregor IA, Williams K, and Goodwin LG (1963) Pyrimethamine and sulphadiazine in treatment of malaria. Br Med J 2:728-729.
151. McKie JH, Douglas KT, Chan C, Roser SA, Yates R, Read M, Hyde JE, Dascombe MJ, Yuthavong Y, and Sirawaraporn W (1998) Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. J Med Chem 41:1367-1370.
152. McNamara JV, Rieckmann KH, Frischer H, Stockert TA, Carson PE, and Powell RD (1967) Acquired decrease in sensitivity to quinine observed during studies with a strain of chloroquine-resistant Plasmodium falciparum. Ann Trop Med Parasitol 61:386-395.
153. Michel R (1968) Comparative study of the association of sulfalene and pyrimethamine and of sulfalene alone in mass chemoprophylaxis of malaria. Med Trop (Mars) 28:488-494.
154. Milhous WK, Weatherly NF, Bowdre JH, and Desjardins RE (1985) In vitro activities of and mechanisms of resistance to antifolate antimalarial drugs. Antimicrob Agents Chemother 27:525-530.
155. Miller KD, Lobel HO, Pappaioanou M, Patchen LC, and Churchill FC (1986) Failures of combined chloroquine and Fansidar prophylaxis in American travelers to East Africa. J Infect Dis 154:689-691.
156. Miller MJ (1957) Further studies on malaria suppression by monthly drug administration. Am J Trop Med Hyg 6:625-637.
157. Molineaux L and Clyde DF (1986) The Epidemiology of Drug Resistance in Malaria Parasites: Report of an Informal Consultation of the Scientific Working Group on Applied Field Research in Malaria. World Health Organization, mimeographed document, Geneva, Switzerland.
158. Montgomery R and Eyles DE (1963) Chloroquine resistant falciparum malaria in Malaya. Trans R Soc Trop Med Hyg 57:409.
159. Mookherjee S, Howard V, Nzila-Mouanda A, Watkins W, and Sibley CH (1999) Identification and analysis of dihydrofolate reductase alleles from Plasmodium falciparum present at low frequency in polyclonal patient samples. Am J Trop Med Hyg 61:131-140.
160. Moore DV and Lanier JE (1961) Observations on two Plasmodium falciparum infections with an abnormal response to chloroquine. Am J Trop Med Hyg 10:5-9.
161. Murphy JR, Clyde DF, Herrington DA, Baqar S, Davis JR, Palmer K, and Cortese J (1990) Continuation of chloroquine-susceptible Plasmodium falciparum parasitemia in volunteers receiving chloroquine therapy. Antimicrob Agents Chemother 34:676-679.
162. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, and Watkins W (2001) Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358:1218-1223.
163. Nagesha HS, Din-Syafruddin Casey GJ, Susanti AI, Fryauff DJ, Reeder JC, and Cowman AF (2001) Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia. Trans R Soc Trop Med Hyg 95:43-49.
164. Nair S, Williams JT, Brockman A, Paiphun L, Mayxay M, Newton PN, Guthmann JP, Smithuis FM, Hien TT, White NJ, et al. (2003) A selective sweep driven by pyrimethamine treatment in Southeast Asian malaria parasites. Mol Biol Evol 20:1526-1536.
165. Ndounga M, Basco LK, and Ringwald P (2001) Evaluation of a new sulfadoxine sensitivity assay in vitro for field isolates of Plasmodium falciparum. Trans R Soc Trop Med Hyg 95:55-57.
166. Newbold CI, Boyle DB, Smith CC, and Brown KN (1982) Stage specific protein and nucleic acid synthesis during the asexual cycle of the rodent malaria Plasmodium chabaudi. Mol Biochem Parasitol 5:33-44.
167. Nguyen DS, Dao BH, Nguyen PD, Nguyen VH, Le NB, Mai VS, and Meshnick SR (1993) Treatment of malaria in Vietnam with oral artemisinin. Am J Trop Med Hyg 48:398-402.
168. Nguyen-Dinh P and Payne D (1980) Pyrimethamine sensitivity in Plasmodium falciparum: determination in vitro by a modified 48-hour test. Bull World Health Organ 58:909-912.
169. Nguyen-Dinh P, Spencer HC, Chemangey-Masaba S, and Churchill FC (1982) Susceptibility of Plasmodium falciparum to pyrimethamine and sulfadoxine/pyrimethamine in Kisumu, Kenya. Lancet 1:823-825.
170. Niven JC (1938) Sulphanilamide in the treatment of malaria. Trans R Soc Trop Med Hyg 32:413-418.
171. Nosten F, Imvithaya S, Vincenti M, Delmas G, Lebihan G, Hausler B, and White N (1987) Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine. Bull World Health Organ 65:891-896.
172. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, and White NJ (1991) Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 337:1140-1143.
173. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, and Watkins WM (2000a) Towards an understanding of the mechanism of pyrimethamine- sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 44:991-996.
174. Nzila AM, Nduati E, Mberu EK, Hopkins Sibley C, Monks SA, Winstanley PA, and Watkins WM (2000b) Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan plasmodium falciparum. J Infect Dis 181:2023-2028.
175. Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, and Watkins WM (1998) Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother 42:164-169.
176. Olliaro PL and Taylor WR (2003) Antimalarial compounds: from bench to bedside. J Exp Biol 206:3753-3759.
177. Omar SA, Adagu IS, Gump DW, Ndaru NP, and Warburst DC (2001a) Plasmodium falciparum in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area. Ann Trop Med Parasitol 95:661-669.
178. Omar SA, Adagu IS, and Warhurst DC (2001b) Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 95:315-319.
179. Omar SA, Bakari A, Owiti A, Adagu IS, and Warhurst DC (2001c) Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. Trans R Soc Trop Med Hyg 95:657-660.
180. Omari AA, Preston C, and Garner P (2003) Artemether-lumefantrine for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev 2:CD003125.
181. Oppenheimer SJ and Cashin P (1986) Serum and red cell folate levels associated with malarial parasitaemia. Trans R Soc Trop Med Hyg 80:169-171.
182. Paget-McNicol S and Saul A (2001) Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. Parasitology 122:497-505.
183. Peters W (1968) Drug resistance and cross-resistance in Plasmodium berghei, in Mode of Action of Anti-Parasitic Drugs (Silva JR and Ferreira MJ eds) pp 33-38, Pergamon Press, Oxford and New York.
184. Peters W (1970) Chemotherapy and Drug Resistance in Malaria. Academic Press, London.
185. Peters W (1975) The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann Trop Med Parasitol 69:155-171.
186. Peters W (1984) Current Antimalarials and New Drug Developments. Springer-Verlag, Berlin, Germany.
187. Peters W (1987) Chemotherapy and Drug Resistance in Malaria. Academic Press, London.
188. Peters W and Robinson BL (1984) The chemotherapy of rodent malaria XXXV. further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'. Ann Trop Med Parasitol 78:459-466.
189. Petersen E (1987) In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination. Trans R Soc Trop Med Hyg 81:238-241.
190. Peterson DS, Di Santi SM, Povoa M, Calvosa VS, Do Rosario VE, and Wellems TE (1991) Prevalence of the dihydrofolate reductase asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian amazon. Am J Trop Med Hyg 45:492-497.
191. Peterson DS, Milhous WK, and Wellems TE (1990) Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87:3018-3022.
192. Peterson DS, Walliker D, and Wellems TE (1988) Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85:9114-9118.
193. Phillips RE, Looareesuwan S, Karbwang J, Warrell DA, White NJ, Kasemsarn P, and Warhurst DC (1984) Failure of chloroquine-erythromycin and chloroquine-tetracycline combinations in treatment of chloroquine-resistant falciparum malaria in eastern Thailand. Lancet 1:300-302.
194. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, et al. (1997) Mutations in plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176:1590-1596.
195. Plowe CV, Djimde A, Bouare M, Doumbo O, and Wellems TE (1995) Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52:565-568.
196. Plowe CV, Djimde A, Wellems TE, Diop S, Kouriba B, and Doumbo OK (1996) Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am J Trop Med Hyg 55:467-471.
197. Plowe CV, Doumbo OK, Djimde A, Kayentao K, Diourte Y, Doumbo SN, Coulibaly D, Thera M, Wellems TE, and Diallo DA (2001) Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. Am J Trop Med Hyg 64:242-246.
198. Plowe CV, Kublin JG, and Doumbo OK (1998) P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. Drug Rests Updates 1:389-396.
199. Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, Chimpeni P, Molyneux ME, and Taylor TE (2004) Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ 328:545.
200. Powell RD, Brewer GJ, and Alving AS (1963) Studies on a strain of chloroquine-resistant Plasmodium falciparum from Colombia, South America. Am J Trop Med Hyg 12:509-512.
201. Powell RD, Brewer GJ, Alving AS, and Millar JW (1964) Studies on a strain of chloroquine-resistant Plasmodium falciparum from Thailand. Bull World Health Organ 30:29-44.
202. Price RN, Nosten F, Luxemburger C, ter KFO, Paiphun L, Chongsuphajaisiddhi T, and White NJ (1996) Effects of artemismin derivatives on malaria transmissibility. Lancet 347:1654-1658.
203. Rabinovich SA (1965) Experimental investigations of antimalarial drug haloquine. III. Investigations of the possibility to restrain the development of chemoresistance to chloridine (Daraprim) by combined administration of chloridine with haloquine. Med Parazitol 34:434-439.
204. Ramakrishnan SP, Prakash S, Chowdhury DC, and Basu PC (1961) Studies on Plasmodium berghei vincke and lips, 1948. XXIX. The size of parasite population and its relation to the selection of a strain resistant to sulphadiazine. Indian J Malariol 15:95-106.
205. Rastelli G, Sirawaraporn W, Sompornpisut P, Vilaivan T, Kamchonwongpaisan S, Quarrell R, Lowe G, Thebtaranonth Y, and Yuthavong Y (2000) Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance. Bioorg Med Chem 8:1117-1128.
206. Rathod PK, McErlean T, and Lee PC (1997) Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 94:9389-9393.
207. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, and Cowman AF (1996) Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 55:209-213.
208. Reeves DS and Wilkinson PJ (1979) The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues. Infection 7 (Suppl 4):S330-S341.
209. Richards WHG (1966) Antimalarial activity of sulphonamides and a sulphone, singly and in combination with pyrimethamine, against drug resistant and normal strains of laboratory plasmodia. Nature (Lond) 212:1494-1495.
210. Rieckmann K, Suebsaeng L, and Rooney W (1987) Response of Plasmodium falciparum infections to pyrimethamine-sulfadoxine in Thailand. Am J Trop Med Hyg 37:211-216.
211. Rieckmann KH (1990) Monitoring the response of malaria infections to treatment. Bull World Health Organ 68:759-760.
212. Rieckmann KH, Campbell GH, Sax LJ, and Mrema JE (1978) Drug sensitivity of Plasmodium falciparum. An in-vitro microtechnique. Lancet 1:22-23.
213. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, Coombs GH, Milhous WK, Tzipori S, Ferguson DJ, et al. (1998) Evidence for the shikimate pathway in apicomplexan parasites. Nature (Lond) 393:801-805.
214. Robertson GI (1957) Experiments with antimalarial drugs in man, iii. Experiments with compound 5943. Trans R Soc Trop Med Hyg 51:457-462.
215. Robertson GI, Davey DG, and Fairley NH (1952) Cross-resistance between "Daraprim" and proguanil. Br Med J 2:1255-1256.
216. Roland S, Ferone R, Harvey RJ, Styles VL, and Morrison RW (1979) The characteristics and significance of sulfonamides as substrates for Escherichia coli dihydropteroate synthase. J Biol Chem 254:10337-10345.
217. Rollo IM (1952a) Daraprim - experimental chemotherapy. Trans R Soc Trop Med Hyg 46:474-484.
218. Rollo IM (1952b) Daraprim resistance in experimental malarial infections. Nature (Lond) 170:415.
219. Rollo IM (1955) Resistance of Plasmodium falciparum to pyrimethamine. Trans R Soc Trop Med Hyg 49:94.
220. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, Mosha F, Chandramohan D, and Sharp B (2003) Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 361:1174-1181.
221. Roper C, Pearce R, Nair S, Sharp B, Nosten F, and Anderson T (2004) Intercontinental spread of pyrimethamine-resistant malaria. Science (Wash DC) 305:1124.
222. Salcedo E, Cortese JF, Plowe CV, Sims PF, and Hyde JE (2001) A bifunctional dihydrofolate synthetase-folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria. Mol Biochem Parasitol 112:239-252.
223. Sano G, Morimatsu K, and Horii T (1994) Purification and characterization of dihydrofolate reductase of Plasmodium falciparum expressed by a synthetic gene in Escherichia coli. Mol Biochem Parasitol 63:265-273.
224. Santos-Filho OA, de Alencastro RB, and Figueroa-Villar JD (2001) Homology modeling of wild type and pyrimethamine/cycloguanil-cross resistant mutant type plasmodium falciparum dihydrofolate reductase. A model for antimalarial chemotherapy resistance. Biophys Chem 91:305-317.
225. Schapira A, Bygbjerg IC, Jepsen S, Flachs H, and Bentzon MW (1986) The susceptibility of Plasmodium falciparum to sulfadoxine and pyrimethamine: correlation of in vivo and in vitro results. Am J Trop Med Hyg 35:239-245.
226. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, Msokame C, Aponte JJ, Tanner M, Mshinda H, Menendez C, et al. (2002) The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 67:17-23.
227. Schellenberg KA and Coatney GR (1961) The influence of antimalarial drugs on nucleic acid synthesis in Plasmodium gallinaceum and Plasmodium berghei. Biochem Pharmacol 6:143-152.
228. Scholer HJ, Leimer R, and Richle R (1984) Sulphonamides and sulphones, in Antimalarial Drugs (Peters W and Richards WHG eds) pp 123-206, Springer-Verlag, Berlin, Germany.
229. Schwartz E, Bujanover S, and Kain KC (2003) Genetic confirmation of atovaquoneproguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 37:450-451.
230. Seaton DR and Lourie EM (1949) Acquired resistance to proguanil (Paludrine) in plasmodium vivax. Lancet 1:394-395.
231. Shaio MF, Wang P, Lee CS, Sims PF, and Hyde JE (1998) Development and comparison of quantitative assays for the dihydropteroate synthetase codon 540 mutation associated with sulfadoxine resistance in Plasmodium falciparum. Parasitology 116:203-210.
232. Shanks GD, Edstein MD, Suriyamongkol V, Timsaad S, and Webster HK (1992) Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg 46:643-648.
233. Shute PG and Maryon M (1954) The effect of pyrimethamine (Daraprim) on the gametocytes and oocysts of Plasmodium falciparum and Plasmodium vivax. Trans R Soc Trop Med Hyg 48:50-63.
234. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, and Nzila AM (2001) Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 17:582-588.
235. Sims P, Wang P, and Hyde JE (1998) The efficacy of antifolate antimalarial combinations in Africa. Parasitol Today 14:136-137.
236. Sims P, Wang P, and Hyde JE (1999) Selection and synergy in Plasmodium falciparum. Parasitol Today 15:132-134.
237. Sirawaraporn W, Prapunwattana P, Sirawaraporn R, Yuthavong Y, and Santi DV (1993) The dihydrofolate reductase domain of plasmodium falciparum thymidylate synthase-dihydrofolate reductase. Gene synthesis, expression and anti-folate-resistant mutants. J Biol Chem 268:21637-21644.
238. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, and Santi DV (1997a) Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 94:1124-1129.
239. Sirawaraporn W, Sirawaraporn R, Cowman AF, Yuthavong Y, and Santi DV (1990) Heterologous expression of active thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry 29:10779-10785.
240. Sirawaraporn W, Sirawaraporn R, Yongkiettrakul S, Anuwatwora A, Rastelli G, Kamchonwongpaisan S, and Yuthavong Y (2002) Mutational analysis of Plasmodium falciparum dihydrofolate reductase: the role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding. Mol Biochem Parasitol 121:185-193.
241. Sirawaraporn W, Yongkiettrakul S, Sirawaraporn R, Yuthavong Y, and Santi DV (1997b) Plasmodium falciparum: asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant. Exp Parasitol 87:245-252.
242. Sirawaraporn W and Yuthavong Y (1986) Potentiating effect of pyrimethamine and sulfadoxine against dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant Plasmodium chabaudi. Antimicrob Agents Chemother 29:899-905.
243. Smithuis FM, van Woensel JB, Nordlander E, Vantha WS, and ter Kuile FO (1993) Comparison of two mefloquine regimens for treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border. Antimicrob Agents Chemother 37:1977-1981.
244. Snow RW, Gouws E, Omumbo J, Rapuoda B, Craig MH, Tanser FC, le Sueur D, and Ouma J (1998) Models to predict the intensity of Plasmodium falciparum transmission: applications to the burden of disease in Kenya. Trans R Soc Trop Med Hyg 92:601-606.
245. Spencer HC (1985) Drug-resistant malaria - changing patterns mean difficult decisions. Trans R Soc Trop Med Hyg 79:748-758.
246. Spencer HC, Watkins WM, Sixsmith DG, Koech DK, and Chulay JD (1984) A new in vitro test for pyrimethamine/sulfadoxine susceptibility of Plasmodium falciparum and its correlation with in vivo resistance in Kenya. Bull World Health Organ 62:615-621.
247. Srivastava IK and Vaidya AB (1999) A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 43:1334-1339.
248. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME, Marsh K, Taylor TE, Watkins WM, and Winstanley PA (2002) Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 360:1136-1143.
249. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, Pinder M, Doherty T, Sutherland C, Walraven G, et al. (2001) Artesunate reduces but does not prevent post-treatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis 183:1254-1259.
250. ter Kuile F, White NJ, Holloway P, Pasvol G, and Krishna S (1993) Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 76:85-95.
251. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, and White NJ (1992) High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis 166:1393-1400.
252. Terzian LA (1970) A note on the effects of antimalarial drugs on the sporogonous cycle of Plasmodium cynomolgi in Anopheles stephensi. Parasitology 61:191-194.
253. Thaithong S, Ranford-Cartwright LC, Siripoon N, Haruyuttanakorn P, Kanchanakhan NS, Seugorn A, Rungsihirunrat K, Cravo PV, and Beale GH (2001) Plasmodium falciparum: gene mutations and amplification of dihydrofolate reductase genes in parasites grown in vitro in presence of pyrimethamine. Exp Parasitol 98:59-70.
254. Thanh NV, Cowman AF, Hipgrave D, Kim TB, Phuc BQ, Cong LD, and Biggs BA (2001) Assessment of susceptibility of Plasmodiura falciparum to chloroquine, quinine, mefloquine, sulfadoxine-pyrimethamine and artemisinin in southern Vietnam. Trans R Soc Trop Med Hyg 95:513-517.
255. Thompson PE and Bayles A (1968) Reciprocal cross resistance between cycloguanil hydrochloride and pyrimethamine in Plasmodium berghei infections in mice. J Parasitol 54:588-593.
256. Thompson PE, Bayles A, Olszewski B, and Waitz JA (1965) Studies on a dihydrotriazine and a sulfone, alone and in combination, against Plasmodium berghei in mice. Am J Trop Med Hyg 14:198-206.
257. Thurston JP (1954) The chemotherapy of Plasmodium berghei. II. Antagonism of the action of drugs. Parasitology 44:99-110.
258. Toyoda T, Brobey RK, Sano G, Horii T, Tomioka N, and Itai A (1997) Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Biochem Biophys Res Commun 235:515-519.
259. Trager W (1958) Folinic acid and non-dialyzable materials in the nutrition of malaria parasites. J Exp Med 108:753-772.
260. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong TH, Tran TT, Stepniewska K, White NJ, et al. (2004) Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363:18-22.
261. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, Samb B, Lagarde E, Molez JF, and Simondon F (1998) Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 321:689-697.
262. Triglia T and Cowman AF (1994) Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 91:7149-7153.
263. Triglia T and Cowman AF (1999) The mechanism of resistance to sulfa drugs in Plasmodium falciparum. Drug Resist Updat 2:15-19.
264. Triglia T, Menting JG, Wilson C, and Cowman AF (1997) Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 94:13944-13949.
265. Triglia T, Wang P, Sims PF, Hyde JE, and Cowman AF (1998) Allelic exchange at the endogenous genomic locus in plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO (Eur Mol Biol Organ) J 17:3807-3815.
266. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, and Ford N (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359:2188-2194.
267. van Dijk MR, Waters AP, and Janse CJ (1995) Stable transfection of malaria parasite blood stages. Science (Wash DC) 268:1358-1362.
268. van Hensbroek MB, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, and Greenwood BM (1995) Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg 89:672-676.
269. van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, Brockman A, Villegas L, Looareesuwan S, White NJ, et al. (2002) Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone- proguanil. Clin Infect Dis 35:1498-1504.
270. Vestergaard Olsen V (1983) Unsuccessful effect of sulfadoxine- pyrimethamine in the treatment of falciparum malaria in Tanzania. Ugeskr Laeger 145:751.
271. Vincke IH and Lips M (1952) Preliminary note on medical prophylaxis with daraprim in rural areas. Ann Soc Belge de Med Trop 32:91-99.
272. Walker AJ and Lopez-Antunano FJ (1968) Response to drugs of South American strains of Plasmodium falciparum. Trans R Soc Trop Med Hyg 62:654-667.
273. Walliker D, Carter R, and Sanderson A (1975) Genetic studies on plasmodium chabaudi: recombination between enzyme markers. Parasitology 70:19-24.
274. Wang P, Brobey RK, Horii T, Sims PF, and Hyde JE (1999) Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol Microbiol 32:1254-1262.
275. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Dao LD, Mshinda H, Tanner M, Watkins WM, et al. (1997a) Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 89:161-177.
276. Wang P, Read M, Sims PF, and Hyde JE (1997b) Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbial 23:979-986.
277. Wang P, Sims PF, and Hyde JE (1997c) A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance. Parasitology 115:223-230.
278. Wangboonskul J, White NJ, Nosten F, ter Kuile F, Moody RR, and Taylor RB (1993) Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur J Clin Pharmacol 44:247-251.
279. Ward SA, Watkins WM, Mberu E, Saunders JE, Koech DK, Gilles HM, Howells RE, and Breckenridge AM (1989) Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 27:781-787.
280. Warhurst DC (1998) Antimalarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance. Drug Discov Today 3:538-546.
281. Warhurst DC (2002) Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Sci Prog 85:89-111.
282. Warhurst DC and Duraisingh MT (2001) Rational use of drugs against Plasmodium falciparum. Trans R Soc Trop Med Hyg 95:345-346.
283. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, and Koech DK (1990) Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 84:492-495.
284. Watkins WM, Mberu EK, Winstanley PA, and Plowe CV (1997) The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 13:459-464.
285. Watkins WM, Mberu EK, Winstanley PA, and Plowe CV (1999) More on 'the efficacy of antifolate antimalarial combinations in Africa'. Parasitol Today 15:131-132.
286. Watkins WM and Mosobo M (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87:75-78.
287. Watkins WM, Percy M, Crampton JM, Ward S, Koech D, and Howells RE (1988) The changing response of Plasmodium falciparum to antimalarial drugs in East Africa. Trans R Soc Trop Med Hyg 82:21-26.
288. Watkins WM, Woodrow C, and Marsh K (1993) Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy. Am J Trop Med Hyg 49:106-112.
289. Wellems TE and Plowe CV (2001) Chloroquine-resistant malaria. J Infect Dis 184: 770-776.
290. White NJ (1994) Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 88 (Suppl 1):S41-S43.
291. White NJ (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41:1413-1422.
292. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, et al. (1999) Averting a malaria disaster. Lancet 353:1965-1967.
293. Wilairatana P, Kyle DE, Looareesuwan S, Chinwongprom K, Amradee S, White NJ, and Watkins WM (1997) Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. Ann Trop Med Parasitol 91:125-132.
294. Williamson J, Bertram DS, and Lourie EM (1947) Effects of paludrine and other antimalarials. Nature (Lond) 159:885-886.
295. Wilson T and Edeson JFB (1953) Acute malaria and pyrimethamine. Br Med J 1:253-255.
296. Winstanley P, Watkins W, Muhia D, Szwandt S, Amukoye E, and Marsh K (1997) Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg 91:322-327.
297. Winstanley PA, Mberu EK, Szwandt IS, Breckenridge AM, and Watkins WM (1995) In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother 39:948-952.
298. Winstanley PA, Watkins WM, Newton CR, Nevill C, Mberu E, Warn PA, Waruiru CM, Mwangi IN, Warrell DA, and Marsh K (1992) The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br J Clin Pharmacol 33: 143-148.
299. Wongsrichanalai C, Wimonwattrawatee T, Sookto P, Laoboonchai A, Heppner DG, Kyle DE, and Wernsdorfer WH (1999) In vitro sensitivity of Plasmodium falciparum to artesunate in Thailand. Bull World Health Organ 77:392-398.
300. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, Magill AJ, and Su XZ (2002) Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature (Lond) 418:320-323.
301. World Bank (1993) World Bank Report: Health. World Bank, Geneva, Switzerland.
302. World Health Organization (1963) Terminology of Malaria and of Malaria Eradication: Report of a Drafting Committee. World Heath Organization, Geneva, Switzerland.
303. World Health Organization (1973) Chemotherapy of Malaria and Resistance to Antimalarials. 529. WHO Technical Report Series. World Health Organization, Geneva, Switzerland.
304. World Health Organization (1984) Advances in Malaria Chemotherapy. World Health Organization Technical Report Series. World Health Organization, Geneva, Switzerland.
305. World Health Organization (1996) Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Falciparum Malaria in Areas with Intense Transmission. World Health Organization, Geneva, Switzerland.
306. World Health Organization (2002) Monitoring Antimalarial Drug Resistance; Report of a WHO Consultation. World Health Organization, Geneva, Switzerland.
307. World Health Organization (2003) Position of WHO's Roll Back Malaria Department on malaria treatment policy. 1-4. WHO Position Statement: 3.
308. Wu Y, Kirkman LA, and Wellems TE (1996) Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc Natl Acad Sci USA 93:1130-1134.
309. Wu Y, Sifri CD, Lei HH, Su XZ, and Wellems TE (1995) Transfection of Plasmodium falciparum within human red blood cells. Proc Natl Acad Sci USA 92:973-977.
310. Yang HL, Liu DQ, Yang YM, Huang KG, Dong Y, Yang PF, Liao MZ, and Zhang CY (1997) In vitro sensitivity of Plasmodium falciparum to eight antimalarials in China-Myanmar and China-Lao PDR border areas. Southeast Asian J Trop Med Public Health 28:460-464.
311. Yao DF and Tang JY (1959) The antimalarial activity of dichlorophenyltriazine and other halogen substituted derivatives. Acta Pharmac Sin 7:84-89.
312. Young MD (1957) Resistance of Plasmodium malariae to pyrimethamine (daraprim). Am J Trop Med Hyg 6:621-624.
313. Young MD, Contacos PG, Stitcher JE, and Millar JW (1963) Drug resistance in Plasmodium falciparum from Thailand. Am J Trop Med Hyg 12:305-314.
314. Yuthavong Y (2002) Basis for antifolate action and resistance in malaria. Microbes Infect 4:175-182.
315. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, Walkinshaw MD, and Yuthavong Y (2003) Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 10:357-365.
316. Zhang K and Rathod PK (2002) Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science (Wash DC) 296:545-547.
317. Zolg JW, Plitt JR, Chen GX, and Palmer S (1989) Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol 36: 253-262.